Prognostic test developed for E2F4 in breast cancer

By looking at the expression levels of downstream genes of the regulators in breast cancer, researchers have identified a gene signature in E2F4 that is predictive of estrogen receptor positive (ER+) breast cancer. The findings define a new opportunity for personalizing medicine for women whose Oncotype DX assay results classify them as of 'intermediate-risk for recurrence.'

Read the whole article on Science Daily

More from Science Daily